Session » Muscle Biology, Myositis & Myopathies Poster II

Date: Monday, November 11, 2019

Time: 9:00AM-11:00AM

Meeting: 2019 ACR/ARP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1292

Abnormal High Density Lipoprotein Particle Size and Number in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1294

Alterations in Activin A-Myostatin-Follistatin System Associate with Disease Activity in Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1287

Anti-mitochondrial Autoantibodies in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1289

Antigen Bead Array versus ELISA to Detect anti-cN1A Antibodies in Patients with Sporadic Inclusion Body Myositis and Correlation with Clinical, Serological and Histological Features

9:00AM-11:00AM: Abstract Number: 1285

Changes in Nail-fold Capillary Abnormalities, and Serum FGF and VEGF Levels in Dermatomyositis Patients with anti-MDA5 Antibody During the Clinical Course

9:00AM-11:00AM: Abstract Number: 1277

Damage and Comorbidities in a Cohort of Patients with Idiopathic Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1282

Female Sex Is a Risk Factor for Failure to Achieve Remission in Polymyositis

9:00AM-11:00AM: Abstract Number: 1290

Identification of Distinctive Interferon Gene Signatures in Different Types of Inflammatory Myopathy

9:00AM-11:00AM: Abstract Number: 1284

Idiopathic Inflammatory Myopathies: Are Muscle Biopsies Still Needed?

9:00AM-11:00AM: Abstract Number: 1297

Increased Hsp90 in Plasma and Muscle Tissue Associates with Disease Activity and Skeletal Muscle Involvement in Idiopathic Inflammatory Myopathies

9:00AM-11:00AM: Abstract Number: 1296

Increased MxA Protein Expression and Dendritic Cells in Spongiotic Dermatitis Differentiates Dermatomyositis from Eczema

9:00AM-11:00AM: Abstract Number: 1278

Inpatient Epidemiology of Dermatomyositis and Polymyositis in the United States

9:00AM-11:00AM: Abstract Number: 1280

JAK Inhibitors: A Promising Molecular-targeted Therapy in Dermatomyositis

9:00AM-11:00AM: Abstract Number: 1288

Line Blot Immunoassay in Inflammatory Myopathies: Diagnostic Accuracy and Factors Predicting Positive Results in Routine Clinical Practice

9:00AM-11:00AM: Abstract Number: 1281

Maintenance Therapy for anti-MDA5-Positive Dermatomyositis Patients with Interstitial Lung Disease: Can They Achieve Drug-Free Remission?

9:00AM-11:00AM: Abstract Number: 1293

Multiple Subpopulations of Lymphocytes Were Absolutely Decreased in Dermatomyositis/polymyositis Patients and Restored by Low-dose IL-2

9:00AM-11:00AM: Abstract Number: 1276

Myositis Specific Antibodies and Clinical Features in Patients from Argentina

9:00AM-11:00AM: Abstract Number: 1274

New Aspects of Clinical and Immunological Characteristics in Patients with Anti-KS Antibody

9:00AM-11:00AM: Abstract Number: 1295

Otoferlin Is Increased in Muscle and PBMCs from Untreated Children with Juvenile Dermatomyositis: Possible Association with Decreased Circulating Natural Killer Cells

9:00AM-11:00AM: Abstract Number: 1286

Patients with Anti-tRNA Synthetase Syndrome Are More Likely to Present to Pulmonary Clinic and Have a Higher Prevalence and Severity of Lung Disease Than Patients with Other Types of Myositis or Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1279

Response Rate and Sustained Remission in Idiopathic Inflammatory Myopathies Receiving Conventional Immunosuppressive Stepwise Management

9:00AM-11:00AM: Abstract Number: 1283

Risk Factors of Cancer-Associated Inflammatory Myopathies: A Multicenter Study

9:00AM-11:00AM: Abstract Number: 1291

Semi-Quantitative and Quantitative Evaluation of Magnetic Resonance Imaging in Patients with Idiopathic Inflammatory Myopathies – a Subanalysis of the Prometheus Study

9:00AM-11:00AM: Abstract Number: 1275

Spectrum of Organ Involvement in Idiopathic Inflammatory Myopathies, Frequency of Comorbidities, and Relationship to Anti-SSA/SSB Positivity

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].